Meg Finch-Jones - Concepedia

Author

Meg Finch-Jones

Also Known As

Finch-Jones, Meg, I Bahar, M D Finch-Jones, M FINCHJONES, M Finch-Jones, M. D. Finch‐Jones, M. Finch-Jones, M.D. Finch-Jones, Meg D. Finch-Jones, Meg Finch-Jones

Publications

6.8K

Citations

H-Index

Concepts

All Affiliations

Southampton General Hospital University Hospitals Bristol NHS Foundation Trust University of Southampton University College London The Christie NHS Foundation Trust

About

Meg Finch-Jones is an author at Southampton General Hospital specializing in medicine, oncology, and surgical oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	9	6.1K
2	Hepatology	6	6	3.8K
3	Health Sciences	4	5	2.5K
4	Pathology	3	3	476
5	Gastroenterology	2	2	433

Meg Finch-Jones

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius, The Lancet Surgical OncologyHepatologyGastrointestinal OncologyColorectal SurgeryMedicine	2008	1.9K
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius, The Lancet Oncology Perioperative Folfox4 ChemotherapySurgical OncologyHepatologyGastrointestinal OncologyColorectal Surgery	2013	1.3K
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study John Primrose, Richard Fox, Daniel H. Palmer, The Lancet Oncology Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementBiliary Cancer	2019	1.2K
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial John Primrose, Stephen Falk, Meg Finch-Jones, The Lancet Oncology Systemic ChemotherapyNew EpocSurgical OncologyHepatologyGastrointestinal Oncology	2014	421
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial John Bridgewater, S. Pugh, Tom Maishman, The Lancet Oncology	2020	227
Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983) Halfdan Sørbye, Murielle Mauer, Thomas Gruenberger, Annals of Surgery	2012	102
Contrast-enhanced intraoperative ultrasound improves detection of liver metastases during surgery for primary colorectal cancer Ankur J. Shah, Mark Callaway, Michael G. Thomas, HPB Medical UltrasoundSurgical OncologyHepatologyMedical ImagingOncologic Imaging	2010	45
A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. John Primrose, Stephen Falk, Meg Finch-Jones, Journal of Clinical Oncology Randomized Clinical TrialSurgical OncologyPathologyOncologyGastrointestinal Oncology	2013	43
Assessment of satisfaction with care after inpatient treatment for oesophageal and gastric cancer V Kavadas, C P Barham, Meg Finch-Jones, British journal of surgery	2004	32
A Prospective Study of Patient Reported Outcomes in Pancreatic and Peri‐ampullary Malignancy Jonathan Rees, Rhiannon Macefield, Natalie Blencowe, World Journal of Surgery	2013	26

Page 1